Search
CTS-21166
go.drugbank.com/drugs/DB06073InvestigationalIn 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent properties in brain penetration, selectivity, metabolic stability … CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far.
Cefaclor
go.drugbank.com/drugs/DB00833ApprovedInvestigationalSemisynthetic, broad-spectrum antibiotic derivative of cephalexin.
FP0011
go.drugbank.com/drugs/DB05090ExperimentalFP0011 is a small molecule antiglutamatergic compound with symptomatic and disease modifying effects in a variety of neurological disorders (amyotrophic lateral sclerosis and Parkinson's disease). … It acts on the presynaptic regulation of glutamate and shows strong neuroprotective properties.
Methdilazine
go.drugbank.com/drugs/DB00902ApprovedMethdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus.
Arundic acid
go.drugbank.com/drugs/DB05343InvestigationalArundic acid has been investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Omega-6 fatty acids
go.drugbank.com/drugs/DB13168InvestigationalNutraceuticalCells involved in the inflammatory response are typically rich in the n-6 fatty acid arachidonic acid, as generally, eicosanoids derived from n-6 PUFA are pro-inflammatory. … Omega-6 fatty acids are polyunsaturated fatty acids with a final carbon-carbon double bond in the n-6 position, that is, the sixth bond, counting from the methyl end.
Synonyms: n-6 fatty acidsZunsemetinib
go.drugbank.com/drugs/DB16502InvestigationalAdditionally, ATI-450 was studied in a terminated trial (NCT05511519) to treat patients with psoriatic arthritis. … Zunsemetinib is being investigated in a new clinical trial (NCT06374459) for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer with bone metastasis.
Drinabant
go.drugbank.com/drugs/DB05750InvestigationalIt is currently developed in obesity and its associated comorbidities. AVE-1625 is also being developed for the treatment of Alzheimer disease. … AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant.
Formic acid
go.drugbank.com/drugs/DB01942ApprovedInvestigationalIt is an important intermediate in chemical synthesis and occurs naturally, most famously in the venom of bee and ant stings. … It is commonly used as a preservative and antibacterial agent in livestock feed.